ASCO 2025: Cell Therapy Abstract Highlights
Our ASCO 2025 Post-Conference Report offers an in-depth analysis and summary of the 95 cell therapy-related abstracts presented at the 2025 ASCO Annual Meeting.
This report is an essential resource for staying updated on the latest developments and innovations in the field of Cell Therapy
Highlights include insights into:
- Therapeutic Class: CAR T cells remained dominant, but there was greater diversity in cell types and non-genetic engineering strategies compared to last year.
- Top Targets: CD19 was the most common disclosed target, with increased focus on B7-H3, alongside emerging targets like CD5
- Disease Breakdown: Lung Cancer was the most popular disease indication, followed by lymphoma, leukemia, ovarian cancer, and skin cancer
- Abstract Summaries for Clinical and Preclinical assets
We hope you find this report valuable and insightful and are as excited as we are to see the latest cell therapy development.
You May Also Be Interested In…
Learn More About Cell Therapy
- The Most Comprehensive Way to Search the Cell Therapy Development Landscape: Unique search ontologies based on Cell Therapy drug and trial characteristics
- Market Leading Approach to Cell Therapy Preclinical & Clinical Data Curation: Manual curation of key Cell Therapy research and development data points by Cell Therapy research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Cell Therapy company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
